Perjeta approved for advanced breast cancer

Share this article:
Perjeta Approved for Advanced Breast Cancer
Perjeta Approved for Advanced Breast Cancer

(HealthDay News) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.

Perjeta was approved for people who haven't been previously treated with an anti-HER2 therapy for metastatic breast cancer, the agency said.

But the FDA warned that unspecified "production issues" facing manufacturer Genentech "could affect the long-term supply of the drug." The agency said the drug maker "has committed to take steps designed to resolve these production issues in a timely manner."

The drug's safety and effectiveness were evaluated in a clinical study of 808 people with HER2-positive breast cancer. The most common side effects noted were diarrhea, hair loss, a decrease in white blood cells, nausea, fatigue, rash, and nerve damage.

The drug was approved with the agency's "black box" label warning of the potential for death or severe effects to a fetus. A woman's pregnancy status must be verified before she starts treatment with the drug, the FDA said.

San Francisco-based Genentech is a unit of the Roche Group.

More information

The FDA has more about this approval.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Cyramza approved by FDA for stomach cancer

Cyramza approved by FDA for stomach cancer

Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach.

Cancer patients require anxiety and depression screening

Cancer patients require anxiety and depression screening

It is important to recognize and treat anxiety or depression among cancer patients, according to a clinical guideline published in the Journal of Clinical Oncology.

Adherence rates for prostate cancer quality of care measures low

Adherence rates for prostate cancer quality of care ...

Adherence to established prostate cancer quality of care measures is frequently low, with considerable regional variation.